Replimune Group Inc. (REPL)
Market Open
11 Sep, 14:07
$
12. 89
-0.35
-2.6057%
$
1.26B Market Cap
- P/E Ratio
- Div Yield
350,341 Volume
-3.52 Eps
$ 13.24
Previous Close 
Want to track REPL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Replimune: Strong Data In A Highly Differentiated Space
Replimune's RP1, an oncolytic immuno-gene therapy, shows promise with a 31.4% ORR in phase 2 trials for post PD-1 melanoma and non-melanoma skin cancers. RP2, adding an anti-CTLA-4 component to RP1, demonstrated a 29.4% ORR in phase 1 trials, with durable responses in difficult-to-treat tumors. Despite competitive challenges and a failed CSCC trial, Replimune's cash runway supports its accelerated approval and phase 3 trials, making it an attractive investment.
Seekingalpha | 2 years ago
Replimune (REPL) Gains on Positive Data From Melanoma Study
Replimune's (REPL) lead pipeline candidate RP1, in combination with Opdivo, leads to an overall response rate of 33.6% in patients with anti-PD1 failed melanoma. Shares gain.
Zacks | 2 years ago
